Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.60 | 72.90 | 0.81% |
| CAC 40 | 8,474.86 | 137.57 | 1.65% |
| DAX 40 | 25,580.88 | 540.60 | 2.16% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,652.87 | 174.53 | 1.67% |
| HKSE | 23,416.78 | 361.75 | 1.57% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,496.56 | 763.41 | 1.11% |
| NZX 50 Index | 13,623.94 | 41.75 | 0.31% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,843.20 | 73.90 | 0.84% |
| SSE Composite Index | 4,056.78 | 27.88 | 0.69% |